Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 13/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20596010 | 0.79 | KDM4E (0.37) | P2RX3KDM4EL3MBTL1 | |
| SCHEMBL6213093 | 0.76 | F2 (0.44) | P2RX3KDM4E | |
| SCHEMBL25213314 | 0.74 | CYP3A4 (0.43) | P2RX3 | |
| SCHEMBL2928884 | 0.74 | SMN1; SMN2 (0.43) | KDM4E | |
| SCHEMBL5906809 | 0.73 | P2RX3 (0.43) | P2RX3KDM4EL3MBTL1SSTR4 | |
| SCHEMBL4832575 | 0.72 | SMN1; SMN2 (0.42) | POLB | |
| SCHEMBL4840210 | 0.71 | POLB (0.46) | P2RX3POLB | |
| SCHEMBL29241474 | 0.70 | S100B (0.42) | P2RX3KDM4EESR1L3MBTL1 | |
| SCHEMBL20596210 | 0.70 | P2RX3 (0.35) | P2RX3KDM4E | |
| SCHEMBL6761751 | 0.70 | TP53 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
| WO-2018237349-A1 | INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | NAMPT 834/4885PDE10A 4121/4885P2RX3 4253/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | NAMPT 802/4885PDE10A 4158/4885P2RX3 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.